Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brilliant Blue G

FDA-approved product (solution, ophthalmic), marketed as Tissueblue.

Registered studies
10
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brilliant Blue G
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Brilliant Blue G. Its therapeutic class is shown instead.

FDA pharmacologic class
Disclosing Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brilliant Blue G in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brilliant Blue G with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison Between Outcomes of Closure of Idiopathic Macular Hole Using Autologus Tenon Capsule Graft and Internal Limiting Membrane Flap Techniques (Pilot Study)

    NCT07633457 · start 2025-11-09

    Registered record
    Registry ID
    NCT07633457
    Conditions
    Macular Hole Surgery; ILM Peeling; Tenon Capsule; ILM Flap; Macular Hole
    Interventions
    vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-11-09
    Completion
    2028-01-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Hole Surgery; ILM Peeling; Tenon Capsule; ILM Flap +1 more
    Interventionvitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]
    PhaseNot applicable
    Registry statusRecruiting

  • Macular Micro Vascular Changes Following Macular Hole Repair : Optical Coherence Tomography Angiography Study

    NCT06233500 · start 2021-12-01

    Registered record
    Registry ID
    NCT06233500
    Conditions
    Macular Holes
    Interventions
    pars plana vitrectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2024-03-15
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Holes
    Interventionpars plana vitrectomy
    PhaseNot applicable
    Registry statusUnknown

  • Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy

    NCT04490876 · start 2020-07-20

    Registered record
    Registry ID
    NCT04490876
    Conditions
    Proliferative Vitreoretinopathy
    Interventions
    3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-20
    Completion
    2020-07-25
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProliferative Vitreoretinopathy
    Intervention3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method
    PhaseNot recorded
    Registry statusCompleted

  • Inverted ILM-flap Techniques Variants for Macular Hole Surgery: Outcomes Comparison

    NCT04135638 · start 2019-11-01

    Registered record
    Registry ID
    NCT04135638
    Conditions
    Macular Holes
    Interventions
    Cover Group; Fill Group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-11-01
    Completion
    2020-04-10
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Holes
    InterventionCover Group; Fill Group
    PhaseNot applicable
    Registry statusUnknown

  • Safety and Efficacy Evaluation of Two Different Brilliant Blue G Dyes as Staining Agent in Vitreo Retinal Surgery.

    NCT05086588 · start 2018-04-04

    Registered record
    Registry ID
    NCT05086588
    Conditions
    Macular Holes; Epiretinal Membrane
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-04-04
    Completion
    2020-06-12
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Holes; Epiretinal Membrane
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Outcomes Based on the Pre-operative Integrity of IS/OS Junction in Idiopathic Epimacular Membrane Surgery

    NCT04158791 · start 2018-03-25

    Registered record
    Registry ID
    NCT04158791
    Conditions
    Epimacular Membrane
    Interventions
    pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-03-25
    Completion
    2019-07-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpimacular Membrane
    Interventionpars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling
    PhaseNot recorded
    Registry statusCompleted

  • Infracyanine Green vs Brilliant Blue G in Macular Hole Inverted Flap Surgery: A Swept Source OCT Analysis.

    NCT03946267 · start 2018-01-09

    Registered record
    Registry ID
    NCT03946267
    Conditions
    Macular Holes
    Interventions
    Inverted inner limiting membrane flap technique for large full thickness macular holes
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-01-09
    Completion
    2018-08-23
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Holes
    InterventionInverted inner limiting membrane flap technique for large full thickness macular holes
    PhaseNot applicable
    Registry statusCompleted

  • Internal Limiting Membrane Peeling-reposition to Treat Idiopathic Macular Holes

    NCT03020459 · start 2017-01-01

    Registered record
    Registry ID
    NCT03020459
    Conditions
    Macular Hole; Surgery
    Interventions
    peeling-reposition; peeling; Brilliant Blue G; postoperative posture; Constellation 23-gauge vitrectomy system
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-01-01
    Completion
    2019-08-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Hole; Surgery
    Interventionpeeling-reposition; peeling; Brilliant Blue G; postoperative posture +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery

    NCT01820520 · start 2013-01

    Registered record
    Registry ID
    NCT01820520
    Conditions
    Macular Hole; Epiretinal Membrane
    Interventions
    brilliant blue G
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-01
    Completion
    2014-02
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Hole; Epiretinal Membrane
    Interventionbrilliant blue G
    PhasePhase 3
    Registry statusTerminated

  • Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy

    NCT01485575 · start 2011-11

    Registered record
    Registry ID
    NCT01485575
    Conditions
    Macular Edema
    Interventions
    Use of intraoperative filters in vitrectomy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2011-11
    Completion
    2028-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Edema
    InterventionUse of intraoperative filters in vitrectomy
    PhaseNot recorded
    Registry statusRecruiting